In today’s healthcare environment, there is an increasing focus on improving the efficiency of rehabilitation processes, given the rising number of injuries and the need to return to active life more quickly.
GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma